EverSource Wealth Advisors’s Cellectis CLLS Stock Holding History

EverSource Wealth Advisors’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41	Sell	13 -183	-93%	-$701	﹤0.01%	4330
2025 Q4	$949	Hold	196	–	–	﹤0.01%	3719
2025 Q3	$559	Buy	196 +183	+1,408%	+$474	﹤0.01%	3922
2025 Q2	$20	Hold	13	–	–	﹤0.01%	4223
2025 Q1	$16	Hold	13	–	–	﹤0.01%	3976
2024 Q4	$23	Hold	13	–	–	﹤0.01%	3701
2024 Q3	$28	Hold	13	–	–	﹤0.01%	3019
2024 Q2	$29	Hold	13	–	–	﹤0.01%	3043
2024 Q1	$33	Hold	13	–	–	﹤0.01%	2873
2023 Q4	$40	Hold	13	–	–	﹤0.01%	2614
2023 Q3	$21	Hold	13	–	–	﹤0.01%	2483
2023 Q2	$26	Hold	13	–	–	﹤0.01%	2472
2023 Q1	$25	Buy	+13	New	+$33	﹤0.01%	2365

Other funds holding CLLS

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EverSource Wealth Advisors's CLLS Position: Q1 2026 in Review

EverSource Wealth Advisors reduced its Cellectis (CLLS) stake by 93% in Q1 2026, selling an estimated $701 and leaving 13 shares worth $41. The position accounts for ﹤0.01% of the portfolio, ranked #4330.

EverSource Wealth Advisors first reported a position in CLLS in Q1 2023 and has held it in 13 quarters since. The position peaked at $949 in Q4 2025. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.

EverSource Wealth Advisors held 13 shares of Cellectis worth $41 as of Q1 2026.
EverSource Wealth Advisors sold 183 Cellectis shares in Q1 2026, an estimated $701.
Cellectis made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #4330 holding.
EverSource Wealth Advisors first reported a position in Cellectis in Q1 2023 and has held it in 13 quarters since.
EverSource Wealth Advisors's Cellectis position peaked at $949 in Q4 2025.
32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.